Back to Search
Start Over
FDA Grants Breakthrough Therapy Designation to LSD-Based Treatment for Generalized Anxiety Disorder: Mind Medicine's lysergide d-tartrate (MM-120) demonstrated statistically significant and clinically meaningful improvements in anxiety symptoms in findings from a phase 2b study
- Source :
- Drug Topics. April 2024, Vol. 168 Issue 3, p18, 1 p.
- Publication Year :
- 2024
-
Abstract
- Mind Medicine has received breakthrough therapy designation from the FDA for its lysergide d-tartrate (MM-120) therapy to treat patients with generalized anxiety disorder (GAD), the biopharmaceutical company announced in a [...]
- Subjects :
- Drug therapy
Generalized anxiety disorder -- Drug therapy
LSD (Drug)
Subjects
Details
- Language :
- English
- ISSN :
- 00126616
- Volume :
- 168
- Issue :
- 3
- Database :
- Gale General OneFile
- Journal :
- Drug Topics
- Publication Type :
- Periodical
- Accession number :
- edsgcl.791885442